Bioasis Announces Issuance of Japanese Patent Relating to xB3™ Platform Technology for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier
GUILFORD, Conn.--(BUSINESS WIRE)--Nov 14, 2019--
Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announces that the Japanese Patent Office (“JPO”) issued Japanese Patent No. 6603227 for the Company’s platform technology.
The patent relates to Bioasis’ P97 conjugates with therapeutic agents where the P97 has the ability to transport the agent across the BBB. These conjugates include xB 3 -001, Bioasis’ lead product conjugate with trastuzumab in development for the treatment of HER2+ breast cancer brain metastases. The issued claims of this patent also cover pharmaceutical compositions containing the conjugates.
“We are excited about the issuance of this patent by the Japanese Patent Office, because it represents a major milestone for our intellectual property protection around our core assets in the Asian market, particularly the important Japanese market. Adding to the already granted patent in Europe, this further strengthens and reinforces our standing around our core technology and our priority program xB 3 -001,” said Company Chair and Chief Executive Officer, Deborah Rathjen, Ph.D. “The Bioasis business model is based on the strength of these assets, the intellectual property that is protected by our broad patent portfolio.”
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB 3 platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis’ internal pipeline programs are focused on treatments for orphan indications, including certain brain cancers, and rare diseases, including Gaucher’s Disease Type II. The Company maintains headquarters in Guilford, Connecticut. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the Company, please visit www.bioasis.us.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191114005725/en/
CONTACT: On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chair of the Board
+1 203 533 7082
KEYWORD: CONNECTICUT UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL GENERAL HEALTH HEALTH CLINICAL TRIALS OTHER HEALTH
SOURCE: Bioasis Technologies Inc.
Copyright Business Wire 2019.
PUB: 11/14/2019 04:05 PM/DISC: 11/14/2019 04:05 PM